Targeted proteomics-determined multi-biomarker profiles developed classifier for prognosis and immunotherapy responses of advanced cervical cancer

• Published in: Frontiers in immunology Vol. 15; p. 1391524
• Main Authors: Li, Jin, Zhang, Xu, Yang, Liuke, Zhu, Youwei, Gao, Rongrong, Zhang, Tiancheng, Chen, Xuwen, Fu, Jun, He, Gaoyang, Shi, Huijuan, Peng, Shenjie, Wu, XiaoHua
• Format: Journal Article
• Language: English
• Published: Switzerland Frontiers Media S.A 21.05.2024
• Subjects: Adult; biomarker; Biomarkers, Tumor - blood; cervical cancer; Female; Humans; Immunology; Immunotherapy - methods; immunotherapy response; Middle Aged; Prognosis; proteomics; Proteomics - methods; Uterine Cervical Neoplasms - diagnosis; Uterine Cervical Neoplasms - immunology; Uterine Cervical Neoplasms - therapy; immunotherapy response; proteomics; biomarker; cervical cancer; prognosis
• ISSN: 1664-3224; 1664-3224
• DOI: 10.3389/fimmu.2024.1391524

Cervical cancer (CC) poses a global health challenge, with a particularly poor prognosis in cases of recurrence, metastasis, or advanced stages. A single biomarker is inadequate to predict CC prognosis or identify CC patients likely to benefit from immunotherapy, presumably owing to tumor complexity and heterogeneity. Using advanced Olink proteomics, we analyzed 92 oncology-related proteins in plasma from CC patients receiving immunotherapy, based upon the comparison of protein expression levels of pre-therapy with those of therapy-Cycle 6 in the partial response (PR) group and progressive disease (PD) group, respectively. 55 proteins were identified to exhibit differential expression trends across pre-therapy and post-therapy in both PR and PD groups. Enriched GO terms and KEGG pathways were associated with vital oncological and immunological processes. A logistic regression model, using 5 proteins (ITGB5, TGF-α, TLR3, WIF-1, and ERBB3) with highest AUC values, demonstrated good predictive performance for prognosis of CC patients undergoing immunotherapy and showed potential across different cancer types. The effectiveness of these proteins in prognosis prediction was further validated using TCGA-CESC datasets. A negative correlation and previously unidentified roles of WIF-1 in CC immunotherapy was also first determined. Our findings reveal multi-biomarker profiles effectively predicting CC prognosis and identifying patients benefitting most from immunotherapy, especially for those with limited treatment options and traditionally poor prognosis, paving the way for personalized immunotherapeutic treatments and improved clinical strategies.